CJClaudio Antonio Da Silva Junior

Claudio Antonio Da Silva Junior

*This is an algorithmically generated author record based on publicly available information.

Claudio Antonio Da Silva Junior has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Drug Development Overview: Targeting Voltage-Gated Calcium Channels for the Treatment of Pain

    by Flavia Tasmin Techera Antunes, Maria Martha Campos, Vanice de Paula Ricardo Carvalho, Claudio Antonio da Silva Junior, Luiz Alexandre Viana Magno, Alessandra Hubner de Souza, Marcus Vinicius Gomez

    Voltage-gated calcium channels (VGCCs) are targeted to treat pain conditions. Since the discovery of their relation to pain processing control, they are investigated to find new strategies for better pain control. This review provides an overview of naturally based and synthetic VGCC blockers, highlighting new evidence on the development of drugs focusing on the VGCC subtypes as well as mixed targets with pre-clinical and clinical analgesic effects.


  • Open Access

    PhTx3-4, a Spider Toxin Calcium Channel Blocker, Reduces NMDA-Induced Injury of the Retina

    by Nancy Scardua Binda, Charles Porto Petruceli Carayon, Rafael Mourão Agostini, Ana Cristina Do Nascimento Pinheiro, Marta Nascimento Cordeiro, Marco Aurélio Romano Silva, Juliana Figueira Silva, Elizete Maria Rita Pereira, Claudio Antonio Da Silva Junior, Célio José De Castro Junior, et al.

    The in vivo neuroprotective effect of PhTx3-4, a spider toxin N-P/Q calcium channel blocker, was studied in a rat model of NMDA-induced injury of the retina. NMDA (N-Methyl-d-Aspartate)-induced retinal injury in rats reduced the b-wave amplitude by 62% ± 3.6%, indicating the severity of the insult. PhTx3-4 treatment increased the amplitude of the b-wave, which was almost equivalent to the control retinas that were not submitted to injury. The PhTx3-4 functional protection of the retinas recorded on the ERG also was observed in the neuroprotection of retinal cells. NMDA-induced injury reduced live cells in the retina layers and the highest reduction, 84%, was in the ganglion cell layer. Notably, PhTx3-4 treatment caused a remarkable reduction of dead cells in the retina layers, and the highest neuroprotective effect was in the ganglion cells layer. NMDA-induced cytotoxicity of the retina increased the release of glutamate, reactive oxygen species (ROS) production and oxidative stress. PhTx3-4 treatment reduced glutamate release, ROS production and oxidative stress measured by malondialdehyde. Thus, we presented for the first time evidence of in vivo neuroprotection from NMDA-induced retinal injury by PhTx3-4 (-ctenitoxin-Pn3a), a spider toxin that blocks N-P/Q calcium channels.